Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902445 | 0.81 | MGLL (0.36) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7500739 | 0.81 | MGLL (0.36) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6669633 | 0.80 | KIF11 (0.36) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2896325 | 0.80 | KIF11 (0.36) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6668549 | 0.74 | DRD1 (0.31) | DRD1DRD5 | |
| SCHEMBL15203337 | 0.71 | — | — | |
| SCHEMBL15203347 | 0.67 | MEN1 (0.32) | — | |
| SCHEMBL2902419 | 0.67 | MEN1 (0.32) | — | |
| SCHEMBL6670190 | 0.66 | DYRK1A (0.34) | DRD1KCNH2 | |
| SCHEMBL6672259 | 0.64 | KCNH2 (0.30) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227096-B1 | 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE | SATO PHARMA (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6525066-B2 | Bactericides; side effect reduction | SATO PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| US-20020173517-A1 | 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure | SATO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
| EP-1227096-A1 | 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE | Sato Pharmaceutical Co. Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173517-A1 | 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure | IL4I1, TLR5, IFNG | SLC6A4 3377/4885SLC6A2 3943/4885SLC6A3 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.